These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 20424624

  • 21. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA.
    Cardiovasc Ther; 2012 Jun; 30(3):e156-66. PubMed ID: 21883995
    [Abstract] [Full Text] [Related]

  • 22. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME.
    J Am Heart Assoc; 2017 Jul 19; 6(7):. PubMed ID: 28724651
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Oktaviono YH, Kusumawardhani N.
    Acta Med Indones; 2020 Jan 19; 52(1):74-79. PubMed ID: 32291375
    [Abstract] [Full Text] [Related]

  • 27. Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure.
    McCullough PA, Rangaswami J.
    Nephron; 2018 Jan 19; 138(3):173-175. PubMed ID: 29207385
    [No Abstract] [Full Text] [Related]

  • 28. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone.
    Berry C, McMurray J.
    Am J Med; 2001 Nov 19; 111(7):587. PubMed ID: 11705445
    [No Abstract] [Full Text] [Related]

  • 29. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC, Figueiredo AE, Barretti P, Pecoits-Filho R, de Moraes TP, BRAZPD Investigators.
    Am J Nephrol; 2017 Nov 19; 46(2):150-155. PubMed ID: 28738355
    [Abstract] [Full Text] [Related]

  • 30. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.
    Eur J Prev Cardiol; 2014 Mar 19; 21(3):299-309. PubMed ID: 24191305
    [Abstract] [Full Text] [Related]

  • 31. Treatment of Hyperkalemia in Heart Failure.
    DeFilippis EM, Desai AS.
    Curr Heart Fail Rep; 2017 Aug 19; 14(4):266-274. PubMed ID: 28656517
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hyperkalemia risk and treatment of heart failure.
    Segura J, Ruilope LM.
    Heart Fail Clin; 2008 Oct 19; 4(4):455-64. PubMed ID: 18760757
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Novel potassium binders as enabling therapy in heart failure.
    Butler J, Khan MS, Anker SD.
    Eur J Heart Fail; 2019 May 19; 21(5):550-552. PubMed ID: 30993820
    [No Abstract] [Full Text] [Related]

  • 37. Future drug discovery in renin-angiotensin-aldosterone system intervention.
    Tamargo M, Tamargo J.
    Expert Opin Drug Discov; 2017 Aug 19; 12(8):827-848. PubMed ID: 28541811
    [Abstract] [Full Text] [Related]

  • 38. The safety of spironolactone treatment in patients with heart failure.
    Anton C, Cox AR, Watson RD, Ferner RE.
    J Clin Pharm Ther; 2003 Aug 19; 28(4):285-7. PubMed ID: 12911680
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.